Protagonist Therapeutics Inc (PTGX)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 675,295 | 336,677 | -536,755 | -409,362 | -283,811 |
| Debt-to-equity ratio | 0.00 | 0.00 | — | — | — |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $675,295K
= 0.00
The debt-to-equity ratio for Protagonist Therapeutics Inc was not available for the fiscal years ending December 31, 2020, and 2021. However, for the years ending December 31, 2022, 2023, and 2024, the company's debt-to-equity ratio is indicated as 0.00. This suggests that the company had no long-term debt compared to its equity during these years, indicating a conservative capital structure where the company mainly relies on equity financing rather than debt to fund its operations and growth. This low ratio may signal a lower financial risk and strong financial health for the company.
Peer comparison
Dec 31, 2024